Terapia biologica con infliximab (anti-TNF) nella malattia di Crohn: analisi delle complicanze.

Antonio Carroccio, Angelo Baldassare Cefalu', Giuseppe Ambrosiano, Angelo B. Cefalù, Antonio Carroccio, Lidia Di Prima, Davide Noto, Giuseppe Pirrone, Giuseppe Ambrosiano, Lidia Di Prima

Research output: Contribution to journalArticle

3 Citations (Scopus)


Anti-tumor necrosis factor (anti-TNF) therapy is an important therapeutic addition in the treatment of active Crohn's disease. Although controlled trials have confirmed the efficacy of anti-TNF (infliximab) treatment, serious toxicities related to the therapies have emerged. The purpose of this article was to review the safety profile of infliximab, and in particular analyse the infectious complications, the autoimmune disorders and the theoretical risk of cancer and lymphoma
Original languageEnglish
Pages (from-to)108-112
Number of pages5
Publication statusPublished - 2006

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'Terapia biologica con infliximab (anti-TNF) nella malattia di Crohn: analisi delle complicanze.'. Together they form a unique fingerprint.

Cite this